Effectiveness of nimodipin on non-traumatic subarachnoid hemorrhage based on computed tomography angiography

In this study, we aimed to investigate the effectiveness of nimodipine on cerebral vasospasm in patients with SAH by evaluating their blood pressure and the GCS. This retrospective study was performed at the Department of Neurology, Soetomo Teaching Hospital, Surabaya. The study participants were those who had been diagnosed with non-traumatic subarachnoid hemorrhage and received nimodipine between January and December 2015. The results indicated that more than 70% of patients received 60 mg oral nimodipine per day for more than 21 days. The calcium antagonist decreased the proportion of patients with poor outcomes and ischemic neurological deficits after aneurysmal subarachnoid hemorrhage. The risk of rebleeding from an aneurysm was more than 5% in the first 24 h, which gradually decreased over time. There were no significant changes in the GCS and blood pressure between patients with SAH who received nimodipine therapy. However, changes in the GCS and blood pressure were observed during the administration of nimodipine